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1. Introduction

1.1 Vaccinations and Autoimmune Diseases 

Vaccine administration is a very effective tool to prevent infectious diseases, but its powerful stimulus on the immune system has generated the fear of exacerbating previously diagnosed autoimmune diseases. Such a fear is also a consequence of the generally anecdotal observation of post-vaccine autoimmune reactions in few previously healthy susceptible individuals. Moreover, vaccine-related autoimmune reactions have also been observed in animal models and extrapolated to man. 
The possible role of vaccines in autoimmune disease induction is, however, difficult to prove in humans, considering the need to perform large, complex, and expensive epidemiological studies, thus limiting their availability [1]. Furthermore, patients with autoimmune diseases have a higher risk, which may be estimated to be approximately double that of the general population for developing infections, mainly at respiratory level, as a consequence of a dysregulated immune system as well as of immunosuppressive treatment [2]. 
In the last few years, in fact, the growing availability of even more powerful immunosuppressive therapies, including biological agents, has allowed to better control autoimmune diseases, but at the price of a more pronounced immune suppression, which exposes patients to a higher infection risk [3], whose prevention, via specific available vaccinations, is crucial. Nevertheless, vaccine coverage in patients with autoimmune diseases is still relatively low [4–6], largely for lack of recommendations by medical doctors [4, 5]. 
Sowden et al. could establish, in fact, that the percent of immunized patients with rheumatic diseases under major immunosuppressive therapy but without co-morbidities representing risk factors for infections, was significantly lower than the percent of patients with co-morbidities (53% versus 95% and 28% versus 64% for flu and pneumococcal vaccination, respectively), largely due to the less common offer of vaccination by the primary care physicians [4]. In another study in the UK, only 37% of patients with chronic inflammatory diseases under immunosuppressive therapy had received both influenza and pneumococcal vaccinations [5], and the situation is no different in France [6]. 
Thus, analyzing the problem, elaborating and releasing clear guidelines on the right use of vaccines, and sensitizing the general population and healthcare workers on the vaccine usefulness play a pivotal role in avoiding unfounded fears or presumed contraindications that may keep a large part of the population away from vaccinations, even in severe circumstances, like pandemic periods [7, 8]. 
In a recent issue of the International Reviews of Immunology,  the matter has been extensively analyzed  by Salemi and D’Amelio grading the studies analyzed  from I to IV and from A to D the levels of evidence and the corresponding grades of recommendation, respectively [9]. 


 
1.2 Could Autoimmunity Be Induced by Vaccination?

This hypothesis, formulated on the basis of generally anecdotal case reports, is difficult to prove, due to the complexity to set up the needed larger and expensive epidemiological studies. Moreover, the existing studies are generally not controlled, but only observational, thus intrinsically having a rather low level of evidence, and hardly comparable among them [10]. 
Although suggestive data have, therefore, been seldom reported, no conclusive evidence has emerged [11]. 
Actually, autoantibody onset may occasionally follow vaccination, but activation of the immunological regulatory mechanisms makes the transition to clinically overt disease rare [1]. Only in a few conditions, the association between vaccine injection and autoimmunity onset has reliably been either confirmed, such as in the case of Guillain-Barr´e Syndrome after the 1976 swine influenza vaccine [1, 12–18] and of immune thrombocytopenic purpura after measles/mumps/rubella (MMR) vaccination [1, 12, 13, 19–21], or excluded, such as in the case of insulin-dependent diabetes mellitus (IDDM) and type or timing of different vaccinations [22, 23]. Otherwise, the originally suspected association between hepatitis B vaccine and multiple sclerosis (MS) [24, 25] has not been confirmed by larger studies [26–29], even though it has been more recently reconsidered [30], also through further observational studies [31, 32]. 
The large majority of experimental demonstrations has been performed either in animal models or based on the proven molecular mimicry between vaccine/infectious agents and host antigens. However, it should be underlined that the experimental animal models, although of great speculative importance to infer on the immunological mechanism, may hardly be directly transferred to the situation of vaccines in humans and the only presence of shared epitopes is not sufficient per se to induce disease. Areas of research still include the need to:

• set up larger and well constructed epidemiological studies on vaccine-related autoimmunity onset, in order to obtain more reliable data;

• monitor autoimmune clinical and serological parameters during preregistration studies [1];

• further clarify underlying immunological mechanisms; and

• perform genetic and proteomic systematic studies, in order to identify possible predisposed individuals.


1.3 Are Anti-Infectious Vaccinations Safe and Effective in Patients with Autoimmunity?

The effect of preventive vaccinations has been systematically analyzed up to now, in over 5000 patients with MS, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), IDDM, chronic arthritis in children, myasthenia gravis, or vasculitis. Since the second half of the 1970s, the development of these studies is not casual; only in 1976, in fact, following the swine influenza outbreak in the U.S., the USA National Program for Flu Vaccination recommended to reassess risks and benefits of flu vaccination in SLE [33]. 
In that period, the studies of preventive vaccinations in autoimmune diseases have mainly been addressed to anti-influenza (also swine influenza vaccine) in patients with MS [34–36], SLE [37–40], and RA [41]. In 1979, pneumococcal vaccination in remitting or mild SLE patients was also demonstrated to be safe and immunogenic [42]. 
Since the second half of the 1980s, IDDM has been extensively studied [43–45] and at the end of the 1990s, for the first time, the contemporary administration of more than one vaccine (pneumococcal polysaccharides, tetanus toxoid [TT], and Haemophylus influenzae type b) in remitting SLE patients was demonstrated being safe and immunogenic [46]. 
Only in the last decade did these studies show a net increase, mainly with regard to anti-pneumococcal and influenza vaccinations in SLE and RA patients, the latter of which were also under treatment with tumor necrosis factor (TNF)α blockers or other biological agents. 
Safety of vaccination has been demonstrated by the majority of publications, provided that remitting or mild patients were chosen [47–49]; immunogenicity, although protective, was generally lower than in normal controls. 
Data are very poor on the efficacy. In particular, safety and immunogenicity of influenza vaccination in MS, SLE, RA, and vasculitides and of pneumococcal vaccination in SLE, immunogenicity of pneumococcal vaccination in RA, and efficacy of influenza vaccination in MS have all been demonstrated through a high level of evidence studies, thus reaching the highest grade of recommendation. Preventive vaccinations should, therefore, be recommended [50] in patients with low-activity autoimmune diseases. 
To our knowledge, the large part of experience has until now been made with non adjuvanted vaccines, considering that the adjuvanted vaccines (HB, TT) have only been used in less than 20% of immunized patients. Thus, their safety should more widely be evaluated and balanced toward the expected higher immunogenicity, relevant in this group of immune compromised patients. 
The immunosuppressive therapy in patients with autoimmune diseases has reached considerable progress. The growing availability of drugs and biologicals, able to very selectively hit the immune system, but also to induce broad functional consequences, allows to more and more effectively treat the patients, but in parallel exposes them to an increased infection risk. 
The very nature of the disease and the heavy immune suppression cast doubts on safety and immunogenicity of anti-infectious vaccinations in these patients. Vaccination, however, is the only tool to prevent infections, thus improving the prognosis of these patients.Until now, over 2500 patients affected by systemic lupus erythematosus (SLE) and rheumatoiod arthritis (RA) have been systematically studied (table 1). Safety and immunogenity of influenza and pneumococcal vaccinations in RA and SLE patients are exposed in tables 2-3.










Tab 1.  -  Cumulative Number of Vaccinated Patients with SLE and RA

Disease	Influenza vaccine	Pneumoccoccal vaccine	Total
SLE	522	305	827
RA	996 (546)a	710(-357)b(396)a	1706
Total	1518	1015	2533
SLE—systemic lupus erythematosus; RA—rheumatoid arthritis
aRheumatoid arthritis patients under treatment with biological agents and immunized with flu (415 with TNFαblockers, 41 with Rituximab) or pneumococcal vaccine (328 with TNFα blockers, 68 with Rituximab). bThree hundred fiftyseven patients have been vaccinated with both influenza and pneumococcal vaccines.

Tab 2. Clinical (No. of Patients Out of the Total with Post-Vaccine Clinical Exacerbation) and Immunological (No. of Patients Out of the Total with Post-Vaccine New Onset or Rise in Titer of Auto-Antibodies) Safety of influenza and pneumococcal vaccinations in RA and SLE patients

Disease	Vaccine	No. of studies	No. of pts	Clinical safety	Immunolsafety	LoEc	Ref
SLE	Influenza	18(1a16b)	440	1/440 (3.86%)	33/212 (15,56%)	IB	19-24, 27-37, 39
	Pneumo	9(2a7b)	266	2/266 (0,75%)	0/156	IB	40, 41, 43-49
RA	Influenza	11(1a7b)	423	28/423 (6,61%)	ND	IB	23,32,58-62,64,66,68,71
	Pneumo	1b	42	1/42 (2,38%)	ND	IIA	47
SLE—systemic lupus erythematosus; RA—rheumatoid arthritis
aRandomized, double-blind studies. bControlled studies. cLevel of evidence


Tab 3. Immunogenicity (No. of Patients with Antibody Response to Vaccine Antigens Out of the Total) of influenza and pneumococcal vaccinations in RA and SLE patients

Disease	Vaccine	No.of studies	No. of pts	Immunogenicityd	LoEc	References
SLE	Influenza	12(1a11b)	408	185/408 (45,34%)	IB	19-24,28,31,32,36,38,39,40-47,49
	Pneumo	9(2a7b)	254	192/254 (75,59%)	IB	40-47,49
RA	Influenza	11(2a9b)	779	386/779 (49,55%)	IB	23,32,58,62-68,71
	Pneumo	8(1a7b)	702	337/702 (48%)	IB	47,64,73-78
SLE—systemic lupus erythematosus; RA—rheumatoid arthritis
aRandomized, double-blind studies. bControlled studies. cLevel of evidence. dImmunogenicity is expressed for influenza as seroconversion rate (the lower between the 2 A vaccine antigens); for pneumococcal vaccine as proportion of patients with at least twofold antibody increase toward at least two polysaccharide antigens.

Areas of research still include the need to:

• evaluate vaccine safety also in patients with active disease;

• extend experience on safety and immunogenicity of adjuvanted vaccines;
	
• evaluate safety and immunogenicity of not yet explored vaccines or adjuvants.

Finally, a deeper knowledge of vaccine-induced in vivo immune system modulation should also be considered.


1.4 State of Art	

Several publications have reported generally anecdotal cases of autoimmune reactions after preventive anti-infectious vaccinations. Most of the available publications refer to case-reports and observational studies. 
Mechanisms through which vaccines may induce autoimmune diseases are mainly extrapolated by the known capacity of infectious agents against which vaccines are directed to induce autoimmunity, and by animal models and in vitro studies [51]. 
An attempt has been made to organize the topic of post-vaccine autoimmunity onset according to the proven or suggested immunological mechanisms, which may be antigen-specific (molecular mimicry) or non specific (bystander activation) [52–54]. Molecular mimicry is based on the structural similarity between micro-organisms and host antigens, such as either the epitopes recognized by anti-group A β-haemolytic Streptococcus antibodies cross reacting with heart tissue host antigens in rheumatic fever [55] or the produced monoclonal antibodies to measles and herpesviruses cross reacting with self proteins [56]. 
Molecular mimicry may also be identified at T-cell level, like in the model of experimental autoimmune encephalomyelitis (EAE) induced in rabbits through the injection of a hepatitis B (HB) polymerase peptide mimicking myelin basic protein (MBP) in complete Freund’s adjuvant (CFA) [57]. 
Another example is the herpetic stromal keratitis induced by the herpes simplex virus 1 (HSV-1) [52]. It has, in fact, been demonstrated in mice that T helper (Th)1 clones, elicited by HSV-1, were able to cross recognize an HSV-1 peptide and self antigens, such as a corneal protein and immunoglobulin (Ig) G2a. 
It should be underlined that the only presence of shared epitopes is not sufficient per se to induce disease, but it is necessary to have mimicry with a peptide that may be presented to autoreactive T-cell clones [54]. It should, however, be remembered that T cell recognition is characterized by a high level of polyspecificity, according to the Mason’s calculation on the theoretical possibility for one T cell receptor to recognize more than one million different linear epitopes [58]. 
Finally, for an autoimmune disease to occur, in addition to the molecular mimicry, the contemporary presence of an infection or at least of a strong adjuvant, such as CFA, is necessary [55]. 
Bystander activation is mainly inferred from studies of experimental animal models and it is based on the release of sequestered self antigens from the infected host tissue, leading to activation of antigenpresenting cells, able to stimulate preprimed dormant autoreactive T-cell clones [53]. Alternatively, virus-specific T-cells may initiate the process by killing the virus-infected cells aftermigrating to the affected organ, thus releasing self antigen and contributing, with macrophages, to the local high cytokine levels and consequent inflammation [53]. Examples are the encephalomyelitis induced in mice by Theiler’s murine encephalomyelitis virus or type 1 diabetes induced by Coxsackie B4 virus [9, 10] in mice having high levels of islet-antigen specific T-cells. 
In addition to the above-reported examples, these mechanisms have been suggested or demonstrated to be involved in several additional infection- or vaccine-induced autoimmune diseases, such as treatment-resistant Lyme arthritis and Borrelia burgdorferi sensu stricto [61], multiple sclerosis (MS) and hepatitis B (HB) vaccine [62,63], Guillain-Barr´e Syndrome (GBS) and Campilobacter jejunii [64], or swine influenza vaccine [65]. These models represent the scientific basis for also interpreting possible post-vaccine autoimmune reactions and provide data in order to avoid molecular mimicry in the construction of new vaccines. 
This may be the case for group A β-haemolytic streptococcal vaccine or vaccine against Neisseria meningitides serogroup B. It should be underlined that animal models may hardly be directly transferred to humans. Moreover, the presence of auto-reactive T-cell clones or the identification of auto-antibodies does not mean that an autoimmune disease will automatically develop following infection or vaccination. For such an event to occur, in fact, it is necessary to satisfy additional pre-conditions, including presence of stimulating cytokines in order to activate a critical mass of autoreactive clones as well as lack of effective regulatory mechanisms [53]. 
Thus, the actual prevalence of autoimmune reactions to vaccination is remarkably low (much less than 1:10,000 of the hundreds of millions vaccine doses yearly administered in the world [66, 67]), probably as a consequence of the many redundant regulatory mechanisms active in the immune system [53]. Nevertheless, the experimental models may provide a biological plausibility [51] to the hypothesis of a link between vaccine administration and autoimmune disease onset, generally formulated on the basis of single case-reports. Only in a few conditions has such an association been more reliably confirmed on the basis of larger observational studies. However, for the majority of the hypothesized associations, larger, complex, and expensive epidemiological studies should be needed, but they are still lacking for the difficulty to be performed [53]. 
Moreover, a vaccine-related autoimmune reaction should meet a series of requirements to be actually considered vaccine-induced [68], including consistency, strength, specificity, and temporal relation. In particular, the reaction should occur in different populations and be observed by different physicians, with a strong epidemiological association, only linked to a specific type of vaccine and within a time-period of a few weeks following vaccination [53]. 
Recently, however, temporal relationship between either infection or vaccination and autoimmunity onset has been challenged, by suggesting a more extensive period involving months/years [69]. Comparing infection- versus vaccine-induced autoimmune reactions, the latter generally show a lower incidence, with the majority of them displaying a milder and self-limiting clinical course [67]. These observations are in agreement with a favorable cost-effectiveness ratio of vaccine use. New onset of auto-antibodies not accompanied by any clinical disease after different vaccine administration has been described. 
Already at the beginning of the 1960s, a transient rise of rheumatoid factor (RF) after immunization of healthy people or rheumatoid arthritis (RA) patients with a variety of vaccines, including tetanus toxoid (TT), typhoid-paratyphoid A and B (TAB), diphtheria, polio, smallpox, and mumps [70, 71] had, in fact, been reported. The inactivated TAB parenteral vaccine, but not the living oral typhoid vaccine, was able to induce a transient IgM RF positivity 15 and 30 days after vaccination, with return to baseline values by 8 months, not associated with any clinically apparent autoimmune disease [72]. 
An inactivated vaccine against Coxiella burnetii, the etiological agent of Q fever, was able to induce in recipients the onset of anti-Ig antibodies (anti-Fab [40%], anti-IgA [20%], and anti-IgG and IgM [15%]), not accompanied by any clinical sign [73]. Recently, Toplak et al. observed an increase or appearance of auto-antibodies in 15 and 13% of 92 apparently healthy medical workers (with a baseline high rate of auto-antibody positivity), 1 and 6 months after flu vaccination, respectively, suggesting de novo induction of auto-antibodies after influenza vaccination in selected individuals [74]. 
Clinical syndromes described after vaccination mainly include neurological pictures represented by MS, acute disseminated encephalomyelitis (ADEM), optic neuritis (ON), transverse myelitis (TM), GBS, and brachial neuritis (BN). Immune thrombocytopenic purpura (ITP), rheumatic syndromes, such as RA, systemic lupus erythematosus (SLE), vasculitis, reactive arthritis, Sjogren’s syndrome and inflammatory myopathies (IM), myopericarditis, or finally, insulin- dependent diabetes mellitus (IDDM) have also been described [67]. 
Among the several reports of autoimmune diseases whose onset has been attributed to vaccinations in predisposed individuals, those reliably vaccine-associated may be considered GBS after 1976 swine influenza vaccine, ITP after MMR vaccination [53, 88, 89], and myopericarditis after smallpox vaccination [88], whereas the suspected association between HB vaccine and MS [62, 63] has not been subsequently confirmed [80–82], even though it has been recently reconsidered [82–85], and the one between childhood immunization and IDDM seems, by now, to be definitively reduced [67, 86, 87]. 
However, the need to perform larger and well-constructed epidemiological studies on vaccine-related autoimmunity onset, in order to obtain more reliable data, should be underlined. In conclusion, the relationship between vaccinations and autoimmune diseases should be considered in a complex and bidirectional way; vaccinations, in fact, prevent infections, which may in turn trigger autoimmunity, but, on the other hand, vaccinations themselves, by a specific mechanism of molecular mimicry, or a non specific mechanism of bystander activation or finally by yet unknown mechanisms, may trigger autoimmunity [90]. 
However, although vaccine administration has been associated with autoimmune manifestations in selected predisposed individuals, who may not be currently identified [53], their very low incidence and mild clinical course, generally lower and milder than those associated with natural infections [67], combined with the general lack of high level of evidence, should not induce to abstain from the immunization practice considering the favorable cost-effectiveness ratio of vaccine use. 
However, areas of research still include the need to develop autoimmune clinical and serological monitoring during preregistration studies [53], perform genetic and proteomic systematic studies in order to identify possible predisposed individuals, and finally, further clarify underlying immunological mechanisms exerted by vaccines/adjuvants.








1.5 Rheumatoid Arthritis

Influenza Vaccine

In 1979, in a controlled study on 17 RA patients treated with influenza bivalent vaccine (A/New Jersey/76 and A/Victoria/75), six of them developed a slight disease reactivation within 3 weeks from vaccination, a figure in line with the spontaneous rate of flare-ups. Moreover, vaccine immunogenicity was comparable between the two groups of RA patients and normal controls. In particular, 3 weeks after immunization 11/17 (65%) RA patients presented a fourfold antibody titer increase towards both vaccine antigens [93]. 
In 1988, Turner Stokes et al. observed an impaired in vitro antibody response to influenza vaccine antigens in 2/10 immunized RA patients [94]. 
In 1994, Chalmers proposed including RA patients in the standard immunization programs, on the basis of a randomized double-blind, placebo-controlled study on 126 RA patients, half of whom were vac- cinated for influenza. The rate of flare-ups was the same in both vaccinated and non-vaccinated RA patients, and also the rate of an- tibody titer increase was comparable among the 63 vaccinated RA pa- tients and 61 vaccinated healthy controls. Regarding immunogenicity, seroconversion rate in RA patients was 77% for A/H3, 50% for A/H1, and 37% for B antigen [128].
In 1994, Cimmino and colleagues performed a retrospective study during a four-month period based on interviews of all consecutive RA outpatients about previous influenza vaccination and disease flares in the month following immunization. Thirty out of 123 evaluated patients had received at least one influenza vaccination during their lifetime and 23/123 had been vaccinated during the year of the study. RA flare was reported in 6/30 patients after vaccination, a rate similar to the expected rate of spontaneous exacerbation [129]. 
In 1996, Francioni et al. could demonstrate safety and satisfying immunogenicity of influenza vaccination by an open study including 40 RA patients divided into two groups (26 in remission and 14 with active disease) compared to healthy controls, all immunized during the 1991–1992 winter season. Regarding safety, they observed disease worsening in 8/40 RA patients. The antibody response was adequate to provide protection from the infection in 27/40 RA patients [130]. 
In 2003, Iyngkaran et al. reported severe vasculitis onset in a young female RA patient 2 weeks after flu vaccination with an inactivated trivalent vaccine [131].
Since 2006, different studies on flu vaccination in RA patients under treatment with both Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and tumour necrosis factor (TNF)α blockers have been pub- lished. In particular, Fomin et al. in 82 RA patients under treatment with DMARDs (either MTX alone or MTX and PDN) and TNFα blockers (22/82 with Infliximab [INF] and 5/82 with Etanercept [ETN]) and 30 age- and sex-matched healthy controls, did not observe any significant RA clinical or laboratory worsening after flu vaccination with a split in- activated vaccine without adjuvant. Moreover, vaccine immunogenicity was adequate 6 weeks after vaccination, considering that seroconver- sion rate was 67% for B antigen and 53% for A/H3 and A/H1 [132]. 
Del Porto et al. analyzed 10 RA patients with low-moderate (DAS28 < 4) and stable disease activity, two of whom were under treatment with TNFα blockers, before and after vaccination with a flu inactivated split vaccine without adjuvant [102]. Ten RA non-vaccinated patients and ten vaccinated healthy people were considered as controls. All pa- tients (vaccinated and non) were treated with PDN <10 mg/daily plus either MTX (10 mg/weekly) or cyclosporine A (CyA <3 mg/kg/daily). No significant difference between vaccinated and non-vaccinated RA patients was observed regarding DAS28 modifications and flare-up inci- dence (2/10 vaccinated versus 3/10 non-vaccinated control RA patients). Furthermore, lymphocyte subpopulations, including regulatory T cells, did not show any significant modification in RA patients, compared with controls, 1, 3, and 6 months after vaccination. Finally, specific antibody response toward flu vaccine antigens was quite a bit lower in patients than healthy controls. In particular, seroconversion rate was 40% for A/H1, 50% for A/H3, and 20% for B antigen. No RA patient developed influenza during the 6-month follow-up. Stojanovich could demonstrate safety of trivalent flu vaccine in 23 RA patients in sta- ble condition longitudinally observed together with 31 non-vaccinated RA control patients; the vaccine was, in fact, well tolerated and the number of respiratory infections was significantly lower in vaccinated patients. In particular, 0/23 versus 0/31 cases of pneumonia, 1/23 ver- sus 7/31 cases of acute bronchitis, and 2/23 versus 19/31 cases of viral respiratory infections, respectively, were observed [104]. 
In 2007, Kapetanovich et al. studied 149 RA patients (62 treated with TNFα blockers alone or combined with DMARDs other than MTX, 50 with TNFα blockers and MTX, and 37 with MTX alone) and 18 healthy subjects, simultaneously vaccinated with trivalent inactivated flu and pneumococcal polysaccharide vaccines. Seroconversion rate of unprotected RA patients at baseline was 60.58% for A/H1, 60.83% for A/H3, and 81.63% for B antigen. Lower flu antibody response was ob- served in RA patients under treatment with TNFα blockers alone or combined with DMARDs [133]. 
In a randomized, double-blind, placebo- controlled, multicenter study, Kaine et al. in the same year, analyzed 208 RA patients treated with either MTX and placebo or MTX and Adal- imumab (ADA) and who were simultaneously vaccinated with trivalent influenza and pneumococcal polysaccharide vaccines. Four weeks after vaccination, specific antibody response toward flu vaccine antigens was lower in RA patients under ADA. In fact, the seroconversion rates in the two groups were 56% versus 50.5% for A/H1, 67.9% versus 58.6% for A/H3, and 60.6% versus 48.5% for B antigen, respectively. However, if the antibody levels at baseline were considered, the patients with protective titers showed antibody response after vaccination compara- ble with that of RA patient group receiving placebo [134]. 
Kubota et al. in 27 RA patients under treatment with TNFα blockers (11 with INF and 16 with ETN), 36 under treatment with DMARDs alone, and 52 healthy controls all vaccinated with trivalent flu vaccine, observed a higher seroconversion rate in the patient group under treatment with TNFα blockers. In particular, in the group under treatment with TNFα blockers, the seroconversion rate was 44.44% for A/H1 and A/H3 and 26.63% for B antigen, whereas in the other group the corresponding values were 22.22%, 33.33%, and 22.22% [135]. 
In a prospective cohort study in 2005, 79 RA patients (52 under treatment with TNFα blockers and 27 with DMARDs) and 18 healthy controls showed adequate antibody response four weeks after flu vac- cination with a subunit vaccine, although antibody titers and serocon- version rate were lower in RA patients treated with TNFα blockers. In particular, in this group the seroconversion rate was 50% for A/H3, 46.15% for A/H1 and B, whereas in the group under DMARDs the cor- responding values were 44.44%, 51.85%, and 66.6% [136]. 
Elkayam and colleagues performed a study on 43 RA patients and 17 healthy controls, immunized with split flu vaccine contain- ing A/NewCaledonia/20/1999, A/Wisconsin/67/2005, and B/Malaysia/ 2506/2004 antigens. Twenty RA patients were under treatment with INF, while 23 RA patients were only treated with DMARDs. INF- treated patients were further subdivided into two groups: 13 were vac- cinated the same day of INF administration, while seven received the vaccine 3 weeks later. No significant modifications in disease activity have been observed as a consequence of vaccination, but only a slight increase of erythrocyte sedimentation rate 6 weeks after vaccination. In all the explored groups, antibody titer toward the three vaccine antigens increased, except in RA patients immunized 3 weeks after INF administration, in whom a rise of antibody titer only against the B/Malaysia antigen was demonstrated. Moreover, seroconversion rate was 45% for A/H1, 60% for A/H3, and 44% for B vaccine antigens [137]. 
In 2009, Salemi et al. in 28 RA patients under treatment with TNFα blockers immunized with influenza vaccine, could confirm vac- cine safety and immunogenicity, but they were also able to demon- strate specific antibody titer persistence at protective levels 6 months after vaccination and strengthened the importance of annual vacci- nation, considering that in a cohort of 18 patients vaccinated each year for 3 consecutive years, the low antibody response to B vaccine antigen could be overcome. Moreover, a significant T regulatory cell increase was observed, only in RA patients, 1 month after vaccina- tion [138]. 
In the same year Nii et al. [139] could demonstrate in 51 RA patients (26 of whom under treatment with TNFα blockers) immu- nized with influenza vaccine and re-evaluated for specific antibodies after 1 year, that protective antibody levels were still maintained by 30.8 and 52.0% of RA patients under treatment with biologicals or not, respectively, versus 46.4% of healthy controls, not a significant difference. Regarding treatment with biologicals different from TNFα block- ers, the response of RA patients treated with anti-B lymphocyte monoclonal antibodies (rituximab [RTX]) to influenza vaccination has been reported in three papers [140–142]. 
First, Gelinck et al. in 2007, observed a lower specific antibody response to flu vaccination in four RA patients under treatment with RTX and MTX than in 19 RA pa- tients under treatment with TNFα blockers with or without DMARDs and 20 healthy controls, all matched for sex, age, and antibody titer at baseline, 84 days after the first RTX administration. From the pre- sented data, seroconversion rate could not be argued [140]. 
The year after Oren et al. evaluated the response to flu vaccine in three groups of subjects (14 RA patients treated with RTX, 29 RA patients treated with DMARDs, and 21 healthy controls). After vaccination, no dis- ease reactivation was observed. Moreover, the seroconversion rate for the A/H3 antigen was significantly lower in RA patients under RTX than in controls (21% versus 67%), whereas no significant difference could be observed in relation to the other vaccine antigens (38% ver- sus 37% for A/H1 and 21% versus 30% for B) [141]. 
In 2010, van Assen confirmed this data on 23 RA patients under RTX, 11 of whom were immunized against influenza 4 to 8 weeks from RTX adminis- tration and 12 after 6 to 10 months, 20 RA patients under MTX, and 29 healthy controls. RTX, in fact, markedly reduced specific antibody response compared to controls, with a slightly restored response 6 to 10 months after RTX administration. From the presented data, sero- conversion rate could not be argued. Regarding safety, DAS28 was not influenced by flu immunization [142]. 
In 2010 in a controlled trial, Bingham [143] enrolled 103 patients with active RA receiving a stable dose of methotrexate (MTX). Tetanus toxoid, pneumococcal polysaccharide, and KLH vaccines as well as a Candida albicans skin test were administered to 1 group of patients receiving rituximab plus MTX (called rituximab-treated patients) for 36 weeks and to 1 group of patients receiving MTX alone for 12 weeks. In this study Rituximab-treated patients had decreased responses to pneumococcal polysaccharide vaccine (57% of patients had a 2-fold rise in titer in response to >or=1 serotype, compared with 82% of patients treated with MTX alone). 
In 2011 Arad  [144] administrated trivalent influenza subunit vaccine to 46 RA patients and to 16 healthy controls. They showed that cell-mediated responses were comparable in RTX-treated vs. DMARDs-treated patients. The recall postvaccination CD4+ cellular response was similar in RA patients and healthy controls. A positive correlation was found between CD19+ cell count on the day of vaccination and cellular response in RTX-treated RA patients The antibody response rate was significantly impaired in the RTX group: being 26.4%, 68.4% and 47.1% in RTX-treated, DMARDs-treated and controls, respectively. 
Elkayam O et Al [145]. showed that vaccination against pandemic H1N1 using an adjuvanted H1N1v monovalent influenza was safe and induced an appropriate response in patients with RA and SLE. 
Saad CG in 2011 [146] studied 1668 ARD patients (systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic sclerosis, psoriatic arthritis (PsA), Behçet's disease (BD), mixed connective tissue disease, primary antiphospholipid syndrome (PAPS), dermatomyositis (DM), primary Sjögren's syndrome, Takayasu's arteritis, polymyositis and Granulomatosis with polyangiitis (Wegener's) (GPA)) and 234 healthy controls that were vaccinated with a non-adjuvanted influenza A/California/7/2009(H1N1) virus-like strain flu. After immunization, seroprotection rates, seroconversion rates and the factor increase in GMT were significantly lower in ARD than controls.  Analysis of specific diseases revealed that seroprotection significantly reduced in SLE, RA, PsA, AS, BD and DM patients than controls. The seroconversion rates in SLE, RA and PsA patients and the increase in GMTs in SLE , RA and PsA patients were also reduced compared with controls. 
In a Ribeiro [147]  study 340 adult RA patients and 234 healthy controls were assessed before and 21 days after adjuvant-free influenza A/California/7/2009 (pH1N1) vaccine. RA and controls showed similar prevaccination GMT and seroprotection (10.8% vs 11.5%). After vaccination a significant reduction  was observed in all endpoints: GMT and factor increase in GMT, seroprotection and seroconversion rates. Disease activity did not preclude seroconversion or seroprotection and remained unchanged in 97.4% of patients. Methotrexate was the only disease-modifying antirheumatic drug associated with reduced responses. Kobie  [148]  showed a decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Compared with healthy controls, RA patients treated with anti-TNF exhibited significantly decreased influenza-specific serum antibody and memory B cell responses throughout multiple years of the study. The short-term influenza-specific effector B cell response was also significantly decreased in RA patients treated with anti-TNF as compared with healthy controls, and correlated with decreased influenza-specific memory B cells and serum antibody present at one month following vaccination. 
In 2012 Mori [149] studied the effect of Tolicizumab (TCZ) therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. In this study TCZ does not hamper antibody response to influenza vaccine in RA patients. Influenza vaccination is considered effective in protecting RA patients receiving TCZ therapy with or without MTX. 
Ribeiro  [150] demonstrated that Abatacept severely reduces the immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. In another  study, Milanovic [151] shown the efficiency, sufficient immunogenicity and safety of modern influenza vaccine application in patients suffering from systemic lupus erythematosus, rheumatoid arthritis or Sjögren's syndrome. 
França IL (​http:​/​​/​www.ncbi.nlm.nih.gov​/​pubmed?term=Fran%C3%A7a%20IL%5BAuthor%5D&cauthor=true&cauthor_uid=22908326​) [152]  compared one hundred and twenty patients (RA, n = 41; AS, n = 57; PsA, n = 22) on anti-TNF agents (monoclonal, n = 94; soluble receptor, n = 26) with 116 inflammatory arthritis patients under DMARDs and 117 healthy controls. They observed no differences in RA patients receiving anti TNF-alpha therapy compared with healthy controls.
In conclusion, despite the evidence coming from only one random-ized and seven controlled but non-randomized studies, inactivated flu vaccine seems generally safe in 996 RA patients (Table I), 540 of whom are under treatment with only DMARDs, the remaining are under treatment with biologicals, 456 with TNFα blockers and 41 with RTX. Immunogenicity in patients treated with DMARDs was generally com- parable to that observed in normal controls, controversial in patients treated with TNFα blockers, and significantly lower in patients under RTX.

Pneumococcal Polysaccharide Vaccine

In 1996, O’Dell et al. studied 40 RA patients before and after pneumococcal polysaccharide vaccine administration; specific antibody response reached protection level in 80% of them 6 weeks after vacci- nation. Response levels were lower in patients under MTX, whereas age, sex, and use of other immunosuppressive agents, such as steroids, AZA, sulfasalazine (SSZ), and HCQ did not appear to be able to influ- ence antibody response [153]. 
In 2002, Elkayam et al. demonstrated vaccine safety and immuno- genicity in 42 RA patients and 20 healthy controls immunized with a 23-valent pneumococcal polysaccharide vaccine. Two months after vaccine administration the number of tender joints was significantly lower than the number observed before vaccination. Only one patient suffered a transient arthralgia and myalgia the day after vaccine ad- ministration. Specific immune response toward seven vaccine antigens 1 month after vaccine administration showed a significant rise of GMT, but with profound differences among the various antigenic serotypes. Moreover, positive response (either at least twofold increase of anti- body titer or reaching serum antibody level of 1 μg/ml) in the patient group was only obtained by 34 to 71% of patients toward the differ- ent antigens, compared with the major percentage observed in healthy controls. Finally, 1/3 of the patients did show either no response to polysaccharide antigens or only to a single antigen and such a poor response was not related to the vitamin B12 or pholate levels nor to the use of immunosuppressive agents, including steroids, MTX, HCQ, or AZA [117]. 
In 2004, the same group performed a comparative study between 11 RA patients under treatment with DMARDs and TNFα blockers (INF or ETN) and 17 RA patients under treatment with only DMARDs, matched for age, sex, length of disease, and use of MTX, before and after a 23-valent pneumococcal polysaccharide vaccine administration. GMT of specific antibodies towards seven of the antigens included in the vaccine 1 month after immunization showed a statistically signifi- cant increase in both groups, even if at a lower level, excepting serotype 14, for the group under treatment with biological agents. Moreover, a significant lower percentage (69% versus 82%) of patients under treat- ment with biological agents showed a positive response toward two or more tested antigens [154]. 
On the contrary, Kapetanovich et al. in a larger study, were able to demonstrate that MTX treatment could negatively influence the response to pneumococcal vaccine. In fact, they studied 149 RA pa- tients (62 under treatment with INF or ETN together with a DMARD other than MTX, 50 under treatment with INF or ETN associated to MTX, and 37 with MTX alone). The percentage of patients with antibody response to the antigens 23F and 6B was 50% in the group under treatment with biological agents without MTX, 32% in the group under treatment with TNFα blockers with MTX, and 13% in the group under treatment with MTX alone [155]. 
Similarly, Visvanathan et al. by analyzing specific antibody response to pneumococcal polysaccharide vaccine in 70 patients with early RA (20 under treatment with INF 3 mg/kg and MTX, 36 with INF 6 mg/kg and MTX, and 14 with placebo and MTX), could conclude that adding INF to MTX did not influence the response to vaccine, evaluated as a twofold increase in the antibody titer toward 12 tested vaccine antigens. In particular, the proportion of patients responding to two or more tested antigens was 64% in the patient group treated with INF 3 mg/kg and MTX, 70% in the group with INF 6 mg/kg and MTX, and 72% in the group under treatment with MTX alone [156]. 
Kaine et al. through a multicenter, double-blind study on 208 RA patients under DMARDs, randomized to receive ADA or placebo, simultaneously vaccinated with 23-valent pneumococcal polysaccharide and trivalent flu vaccines, could demonstrate that the response to pneumococcal vaccine (twofold increase of antibody titer towards at least 3/5 tested antigens) four weeks after vaccination was similar in both groups (37% for ADA-treated versus 40% for placebo), as well as the patient percentage reaching a protective antibody titer (placebo 81.7% versus ADA 85.9%) [134]. 
More recently, Gelinck et al. on 45 RA patients under treatment with DMARDs and TNFα blockers, 28 RA patients treated with only DMARDs, and 18 healthy controls, all immunized with pneumococcal polysaccharide 23-valent vaccine, could observe an antibody response (defined as the percent of subjects with an antibody titer >0.35 μg/ml in addition to at least a twofold increase of antibody titer) toward four polysaccharide vaccine antigens (6B, 9V, 19F, 23F) reduced in RA pa- tients under MTX and even more in RA patients under MTX and TNFα blockers. In particular, 9/24 (36%) patients under only MTX, 4/27 (18%) patients under MTX + TNFα blockers, 6/9 (67%) patients under only TNFα blockers, and 9/13 (70%) of patients without both MTX and TNFα blockers were able to respond according to the above reported parame- ters [157]. 
In 2010, Bingham et al. analyzed 100 RA patients, 32 of whom under MTX and the remaining under MTX + RTX, immunized with TT and 23-valent pneumococcal polysaccharide vaccine. The response to the T-independent pneumococcal polysaccharide vaccine was markedly reduced in the RTX-treated patient group [27/63 (43%) had ≥ twofold antibody rise towards at least two serotypes compared to 22/28 (82%) observed in RA patients treated with only MTX] [158]. 
Also, in 32 patients with Sjo ̈gren’s syndrome, 14-valent pneumococcal polysaccharide vaccine administration was demonstrated as being safe (no clinical or serological disease exacerbation has been observed) and immunogenic (persistence of antibody levels above baseline for 8/14 serotype antigens six months after immunization) already in 1980 through a double-blind, placebo-controlled study [159]. 
Coulson [160] evaluated Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. They analyzed  152 patients, of whom 28 had never been vaccinated against pneumococcus. Median levels of antibodys were significantly higher in those who had been vaccinated. Unvaccinated patients and those taking oral prednisone were more likely to have had pneumonia in the previous 10 years. The RR for developing pneumonia among non-vaccinated patients was 9.7 (p=0.005) and among steroid-treated patients was 6.5 (p=0.001), after adjusting for age, gender, disease duration and comorbidity.  
Kapetanovic et al. analyzing 505 pz concluded that antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors [161]. 
In another study 253 RA patients were studied:  heptavalent pneumococcal conjugate vaccine elicits similar antibody response as standard 23-valent polysaccharide vaccine in adult patients with RA treated with immunomodulating drugs [162]. 
An analysis of 398 patients show  Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different anti-rheumatic drugs [163].
In conclusion, the T-independent pneumococcal polysaccharide vac- cine, until now performed on 710 RA patients (Table I), 328 of whom under TNFα blockers and 68 under RTX, has been shown to be safe; the immunogenicity is heavily reduced by RTX and generally seems to be more compromised by MTX than by TNFα blockers. However, although it should be better to start therapy after vaccination in order to reach optimal antibody response, pneumococcal vaccine administration should be recommended in these patients, even if already under treatment.





1.6 Systemic Lupus Erythematosus

Influenza Vaccine

In 1978–1979, the problem of vaccine administration in SLE patients has been faced in a series of studies [164–168] all addressed to influenza prevention by swine monovalent vaccine antigen A/New Jersey/76 or bi- valent A/New Jersey/76 and A/Victoria/75. These studies demonstrated substantial vaccination safety, despite two cases of glomerulonephritis arising in two patients with active SLE before immunization [166, 167]. 
Moreover, these studies were able to demonstrate an immunogenicity comparable to that of normal controls, except for two papers where SLE patients presented specific antibody titers, after flu immunization with a bivalent inactivated vaccine, lower than the ones observed in age- and sex-matched normal controls [164, 167].
In particular, Ristow et al. by vaccinating 29 SLE patients with an A/New Jersey/76 influenza vaccine, observed a fourfold increase of specific antibody in 14/29 patients, whereas Williams et al. in 6/19, Brodman et al. in 13/46, and Louie et al. in 7/11. The year after, Herron et al. analyzed 20 SLE patients before and after immunization with a bivalent influenza vaccine and could observe four mild flare-ups, whereas the antibody titer was not dissimilar from that observed in normal controls. Finally, the serocon- version rate was 81% for A/New Jersey/76 and 67% for A/Victoria/75 [168]. 
In 1988 Turner Stokes and colleagues reported an impaired in vitro response in 9/28 SLE patients, in correlation with dsDNA auto- antibody levels and independently of disease activity or immunosup- pressive therapy. In the in vitro non-responder group, an in vivo seroconversion could, however, be observed in 23/28 patients, proba- bly related to lymphoid redistribution of antibody-producing cells, as argued by parallel lymph-node analysis [169, 170]. 
Between 2000 and 2002, Abu-Shakra et al. in 24 SLE patients treated with trivalent split flu vaccine, analyzed possible disease re- activation [171], possible appearance/increase of auto-antibodies [172], and specific anti-influenza antibodies [173]. Disease activity was moni- tored by the SLE Disease Activity Index (SLEDAI), a validated tool for disease activity monitoring [174]; no modification was observed 6 and 12 weeks after vaccination [171]. A transient increase of auto-antibodies (anti-Sm, anti-RNP, anti-Ro, anti-cardiolipin) has been observed at 6 weeks, independently of clinical disease activity [172]. Finally, specific anti-influenza antibody response was lower than the one observed in the general population (mainly in <50 years, under treatment with prednisone [PDN] >10 mg per day or azathioprine [AZA], but not methotrexate [MTX]), with a seroconversion rate of the total group of 58% for A/Sidney/97, 62.5% for B/Harbin/94, and 37.5% for A/Bejing/95 [173]. 
In 2004, Mercado et al. reported 18 female SLE patients immu- nized with inactivated flu vaccine and could observe absence of disease reactivation with a protective immunogenicity, even though at lower levels than in healthy controls. In particular, the seroprotection rate (the percent of patients with a geometric mean titer of at least 1:40) was 67%, 72%, and 61% against A/Moskow/10/99, A/New Caledonia 20/99, B/Sichuan/379/99 in SLE patients versus 77%, 94%, and 94%, in healthy controls. The seroconversion rate could not be argued from data presented in the paper [175]. 
In 2006, Holvast et al. [176] and Del Porto et al. [177] described 56 and 14 SLE patients respectively, treated with trivalent split influenza vaccines in the 2003/2004 winter season. In both papers, vaccine safety was observed, provided that quiescent SLE patients were chosen. Regarding immunogenicity, specific antibody titers observed in SLE patients were not significantly different compared to 18 age- and sex-matched healthy controls in the Holvast et al. experience, excepting the seroconversion rate, which was significantly lower than the same parameter observed in normal controls (A/H1 43%, 24/56; A/H3 39%, 22/56; and B 41%, 23/56 versus A/H1 94%, 16/17; A/H3 88%, 15/17; and B 71%, 12/17), this reduction being related to AZA use [176]. Also, Del Porto et al. were able to observe a protective antibody response against influenza virus and a seroconversion rate of 57%, 93%, and 36% for A/Moskow/10/99, A/New Caledonia 20/99, and B/Shangdong/7/97 versus 70%, 50%, and 50% in healthy controls. The vaccine efficacy was clinically evaluated by monitoring three ILI cases observed during the seasonal period, only one of which was actually confirmed by viral identification. Moreover, no increase/appearance of auto-antibodies was observed after flu vac- cination, whereas 2/14 flare-ups have been observed after vaccination versus 1/10 in non-immunized SLE patients [177]. 
In the same year, Tarja` n et al. analyzed the appearance/increase of anti-cardiolipin anti- bodies in 18 low activity, stable SLE patients (8 of whom with a positive history for anti-cardiolipin and/or β2-glycoprotein 1 antibodies) after vaccination with trivalent flu vaccine for three consecutive years. Anti- β2 glycoprotein 1 antibodies increased in 7/8 patients with antibody positivity at baseline, whereas no antibody appearance was observed in ten negative patients at baseline. Moreover, a significant increase of anti-dsDNA antibodies was observed, mainly in the group with base- line positivity of anti-cardiolipin antibodies. However, such immuno- logical modifications were not accompanied by SLEDAI variations nor by thrombotic events [178]. 
Again, in the same year, Stojanovich could demonstrate safety of trivalent flu vaccine in 23 SLE patients in sta- ble condition longitudinally observed together with 46 non-vaccinated SLE patients; the vaccine was, in fact, well tolerated and the number of respiratory infections were significantly lower in vaccinated versus non-vaccinated SLE patients (0 versus 1 pneumonia, 1 versus 17 acute bronchitis, and 5 versus 21 viral respiratory infections) [179]. 
In 2008, however, Stratta et al. described one SLE patient with a se- vere flare-up following flu vaccination, despite SLE were in a quiescent phase, not needing any steroid or immunosuppressive therapy since 14 years [180]. 
In 2009, Holvast et al. analyzed the antibody response to influenza vaccination in 52 SLE patients and 28 healthy controls, by also studying the response to a booster administered after four weeks [181]. In particular, seroconversion rate after the first vaccination was 34.6% versus 28.6% to A/H1N1, 25% versus 10.7% to A/H3N2, 19.2% versus 10.7% to B strain in patients and controls, respectively. Seroprotection rate and geometric mean titers (GMTs) increased similarly in patients and healthy controls after vaccination, whereas the booster did not induce a rise of these values. However, in patients not vaccinated in the previous year, GMTs and seroconversion rate to A/H1N1 increased (from 34.6% to 46.2% with 5/52 [9.6%] negative SLE patients at baseline who se- roconverted) after booster. Finally, the booster has been demonstrated to be safe, considering that no SLEDAI modifications were noticed, but useless, considering that no rise in seroprotection rate or GMTs was observed. The same group in another paper analyzed the specific cell-mediated immune response to A/H1N1 and A/H3N2 vaccine anti- gens through the identification of IFN-γ secreting cells and reported a significant rise one month after vaccination in 54 SLE patients, even though at lower levels than normal controls [182]. The lower cellular response was associated with the use of PDN and/or AZA. 
In the same year, Wallin et al. [183] analyzed 47 SLE patients before and after flu immunization. No SLEDAI modifications were observed and seropro- tection rate was similar in patients and normal controls, whereas se- roconversion rate to A/New Caledonia/20/99 strain was significantly lower in SLE patients than in normal controls (57.4% versus 81.4%, p < 0.04); no significant difference, instead, was observed for serocon- version rate to A/Wisconsin/67/2005 and B/Malaysia/2506/2004 strains (61.7% and 51.1% versus 81.4% and 62.9%, respectively). No inter- ference on antibody response has been observed for MTX and AZA, whereas steroids were able to affect the response to one of the vaccine antigens. 
Finally, in 2010, Wiesik-Szewczyk et al. examined flu vaccine safety and immunogenicity in 62 SLE patients and 47 healthy controls. In particular, one severe and six mild/moderate exacerbations have been observed by three months from vaccination. Moreover, 12 seronegative patients developed low-titer positivity for anti-nuclear and anti-dsDNA antibodies one month after vaccination. Finally, seroconversion rate for H1N1 A/New Caledonia/20/99, H3N2 A/Christchurch/28/03, and B/Jangsu/10/03 strains one month after vaccination in patients versus healthy controls was 53%, 55%, and 56% versus 83%, 85%, and 72%, respectively [184]. 
In conclusion, despite anecdotal cases of disease worsening after vaccination, in- activated flu vaccine, until now administered to 522 SLE patients (Table I), seems generally safe, provided that quiescent patients are chosen. Treatment with PDN >10 mg/daily and AZA, but not MTX, however, may reduce antibody response to levels that are considered protective.



2. Objective

To evaluate the safety and immunogenicity of the trivalent seasonal non-adjuvanted anti-influenza vaccine in RA patients receiving different anti tumour necrosis factor (TNF) agents or inhibitors of co-stimulus compared with patients with RA or SLE receiving DMARDs and healthy controls and the effect of a simultaneous 23-valent anti-pneumococcal or pandemic monovalent MF59-H1N1 adjuvanted vaccine. Moreover, the effects of biological therapy on cell-mediated immunity following influenza vaccination have been investigated. 

3. Materials and Methods

Eighty-five RA patients, diagnosed on the basis of the American College of Rheumatology criteria [185], age range 32–83 years, 68 females, under treatment with TNFα blockers, Infliximab (14), Etanercept (33), Adalimumab (24) or the inhibitor of co-stimulus Abatacept (14), have been vaccinated, after informed consent, by intramuscular route with 0.5 trivalent non-adjuvanted split influenza vaccine [Vaxigrip, Sanofi Pasteur MSD] for a total amount of 85 vaccine injections, at least once during three consecutive influenza seasons (2008–2009, 2009–2010 and 2010–2011). In particular, 19, 30 and 36 patients were vaccinated in each influenza season, 6 and 14 of whom represented a stable patient cohort vaccinated respectively in the first and second, and in the second and third influenza seasons. Flu vaccine contained 15 μg for each viral strain per dose: A/Brisbane/59/07 (H1), A/Brisbane/10/07 (H3), B/Florida/4/06 in season 2008–2009, A/Brisbane/59/07 (H1), A/Brisbane/10/07 (H3), B/Brisbane/60/08 in season 2009–2010 and A/California/7/2009  (H1), A/Perth/16/09 (H3), B/Brisbane/60/08 in season 2010–2011.
Inclusion criteria were low-moderate activity (full joint count disease activity score [DAS] < 3.7) [186] and stable (disease not needing any increase of therapy for at least 6 months) disease, whereas exclusion criteria were any sort of contraindication (referred allergy for egg or any vaccine component, pregnancy, etc.) at the time of enrolment.
Forty-two age and sex-matched healthy controls (HC) received, after informed consent, the same flu vaccine at least once during the above reported three consecutive influenza seasons.
In the second season 30 RA patients (13 HC) received simultaneously a single dose of the pandemic monovalent MF59-adiuvanted influenza vaccine (A/California/7/2009 (H1)) [Focetria, Novartis].
In the first and third season, instead, respectively 19 and 15 RA (10 and 6 HC) patients received simultaneously 23-valent polysaccaride pneumococcal vaccination [Pneumovax 23, Merck]. 
In the last season 16 low activity (systemic lupus erythematosus disease activity index [SLEDAI] <12 [174])  SLE and 9 RA patients under treatment with only DMARDs  (DAS < 3.7) were also enrolled.  
All the patients were recruited among the outpatients attending the clinic of Clinical Immunology and Rheumatology of the Sant'Andrea University Hospital in Rome.
All vaccinated RA patients were treated with low dose steroids (<10 mg/daily of prednisone) and methotrexate (10-15 mg/weekly)  or cyclosporine (<3 mg/kg/daily). and presented stable disease activity [defined as the disease not needing any increase of therapy for at least 3 weeks for SLE and 6 months for RA]. For SLE, all patients that at the time of enrolment had disease activity involving central nervous system or kidney have been excluded.	
They underwent clinical and laboratory (specific anti-influenza virus antibodies, antinuclear antibodies [ANA], peripheral blood lymphocyte [PBL] subpopulations) evaluation before (T0) and 30 (T1) and 180 (T2) days after vaccination. Blood samples were collected from HC at the same times.




3.1 Safety

Safety has been monitored at T0, T1 and T2 with:

1)	DAS and SLEDAI for RA and SLE, respectively,  to register possible vaccine-induced disease reactivation. 
2)	All patients were given a diary card in order to register possible local and systemic adverse reactions. Moreover, 1 week after vaccination all the patients have been interviewed by telephone calls and asked about the possible appearance of a list of clinical systemic and/or local side effects including: shivering, fever (>37.5°C), headache, malaise, asthenia, arthralgia, myalgia, local pain, redness, induration or swelling.
3)	Laboratory evaluation, including erhytrocite sedimentation rate (ESR), C reactive protein (CRP), blood cell count, Rheumatoid Factor (RF), Anti-nuclear antibodies (ANA)

The study was approved by local ethics committee. 

3.2 Laboratory Evaluation

Specific anti-Influenza Antibodies

Sera were analyzed by hemagglutination-inhibition (HAI) test, according to standard procedures. Antigens used for testing were the same or antigenically equivalent to those included in the vaccine formulations. Each serum was tested at a starting dilution of 1:10. Geometric mean titers (GMTs), seroprotection rate (SP) (the percentage of vaccine recipients with a serum HAI titer of at least 1:40 after vaccination), seroconversion rate (SC) (the percentage of vaccine recipients with an increase in serum HAI titers of at least fourfold after vaccination) and seroconversion factor (SCF) (the post-vaccination antibody titer divided by the pre-vaccination antibody titer) were calculated. A seroprotection rate exceeding 70% (60% in people aged >60 years), a seroconversion rate exceeding 40% (30% in people aged >60 years) and a seroconversion factor exceeding 2.5 (2 in people aged >60 years) were considered as cut-off levels of vaccine immunogenicity for adults 18–60 years old, according to the guidelines of the Committee for Human Medicinal Products (CHMP). To fulfill the CHMP guidelines for the seasonal flu vaccination each of the 3 vaccine antigens must meet at least one of the above criteria while all criteria must be met for pandemic.vaccination [187].

Specific anti-Pneumococcal Antibodies

Their determination was performed only in the first season for antigens 4 and 14 one month after pneumovax23  immunization. A positive immunization response was deﬁned as a 2-fold or higher increase compared with the prevaccination antibody concentration. Since a protective level of serum antibody has not been strictly deﬁned and may differ among serotypes, these values were not used to identify individuals with probable/possible protective antibody levels.
Levels of serotype-speciﬁc pneumococcal IgG to 4 and 14 were measured using commercing available enzyme-linked immunosorbent assay (ELISA) for quantitation of human IgG antibodies speciﬁc for S. pneumoniae capsular polysaccharides. Brieﬂy, ELISA plates were coated with Pn PS. Dilutions of human sera absorbed with pneumococcal capsular polysaccharide were then added to the ELISA plates. The serotype-speciﬁc antibodies were detected using goat anti-human IgG antibodies conjugated with alkaline phosphatase, followed by addition of the substrate, pnitrophenyl phosphate. The optical density was measured at 405 nm using an ELISA plate reader. The optical density of the coloured end product is proportional to the amount of anticapsular PS present in the serum. The lower limit of detection was 0.01 mg/l.


Autoantibodies

RA sample sera were evaluated for ANA by indirect immune-fluorescence. (Alifax Diagnostica S.p.A., Padova, Italy); rheumatoid factor (RF) was assessed by nephelometry (Aeroset, Abbott Diagnostics, Abbott Park, IL, USA), according to the manufacturer’s instructions.


Peripheral Blood Moninuclear Cells (PBMC)

Preparation of PBMC samples

PBMC were isolated from heparinized whole blood by density gradient centrifugation using Ficoll-hypaque (Bio-Lynx, Brockville, Canada) and washed three times in phosphate-buffered saline (PBS). Aliquots of 1×107 cells were dispensed in Cryovials (Nunc) and placed in a freezing device (Nalgene). 

Lymphocyte Subpopulations

Lymphocyte subpopulations, including evaluation of regulatory CD3+/CD4+/CD8−/CD25 bright/CD127 dimT cell frequency was performed on patients and healthy controls vaccinated in the first flu season.
T-regs subpopulations were studied by a standard protocol based on five-color immune-fluorescence flow cytometry analysis. Cells were surface stained using a panel of fluorochrome-conjugated mAb including: PerCP-CD3, FITC-CD19, FITC-CD4, APC-CD8, PE-CD45, PE-CD25, CD127 Alexa 647-conjugated (Becton Dickinson, S.p.A.) and incubated for 30 min in the dark at room temperature. Preparations were washed and fixed using the fluorescence-activated cell sorter (FACS) lysing solution (Becton Dickinson Immunocytometry System, Mountain View, CA, USA) according to the manufacturer's instructions. In particular, Tregs have been identified by the following panel: CD3+, CD4+, CD8−, CD25bright, CD127dim, and expressed as a percentage of CD4+ lymphocytes. Flow cytometry was performed using a FACScanto 1 (Becton Dickinson Immunocytometry System, Mountain View, CA, USA) flow cytometer. Forward and side light scatterswere used to only include lymphocytes in the analysis. Twenty thousand lymphocytes were tested for each sample. Data were analyzed by the dedicated “Diva 2.0 software”.

PMA-iono stimulated samples

PBMCs from 6 patients and 3 matched controls vaccinated in the second season at T0, T1, T2 were simultaneously thawed and batch-processed. Cells were stimulated with 20 ng/ml phorbol 12-myristate 13-acetate (PMA) and 1 μg/ml ionomycin (Sigma-Aldrich, St. Louis, MO) at 37°C for 5 h to detect the frequencies of IL-17, TNF-α and IFN-γ-producing T cells. Brefeldin A (1,5 μg/ml; Sigma) was added to cultured PBMCs for 3 h. The stimulated PBMCs were washed in phosphate buffered saline  and incubated for 30 minutes at the dark and at 4 C° with CD4-Pe-Cy7, CD8-APC-Cy7, CD69-PerCp.  Then PBMCs were fixed in 4% formaldehyde, permeabilized with 0.1% saponin (Sigma), and stained with IFN--FITC, IL17a-Pe, TNFα-APC.  One hundred thousand events per sample were acquired using a FACS Canto flow cytometer and analysis was performed with FACSDiva software (BD Biosciences). 
Non-antigen specific functional responses at three times points (IL-17a, TNFα and IFNγ) were assessed gating on T lymphocytes, followed by gating on CD69+. Among CD69+ we assessed the percentage of cells producing IFNγ, TNF- and IL-17a.


4. Statistical Analysis

All statistical analyses were performed using the Stat Soft 6.0 and GraphPad Software, Inc. program The SCF for the single subjects was derived in a logarithmic (base 10) scale to obtain a roughly normal distribution and its statistical significance  between different groups was determined with a  Student’s t test for unpaired data. Statistical comparison of DAS, SLEDAI and mean percentages of lymphocyte subpopulations was made by Mann–Whitney U and Wilcoxon tests for paired data. Correlations have been explored by the Spearman's coefficient test. Ordinary and repeated measures one-way ANOVA, with Bonferroni post-test correction have been performed for variance evaluation of PMA-iono stimulated cells. P values  ​​<0.05 were considered significant 




5. Results

5.1 Safety

No significant increase of disease activity was found, in both SLE and RA groups, before, 1 and 6 months after influenza vaccination.
Data shown for RA on biologicals are the mean of 3-year values, being representative of the behavior observed in each year (Table 4).
No severe adverse reactions (life-threatening, requiring hospitalization and/or intravenous treatment), were observed. Mild systemic and local side effects are reported in table 5. No significant difference could be observed between vaccinated patients and HC.
No statistically significant changes of the ANA titer, RF and  inflammatory indices have been registered.



Tab 4. DAS or SLEDAI for RA and SLE patients at T0, T1,T2 after flu vaccination
	RA BIO	RA DMARDs	SLE	
Patients N	 85	9	16	
Age mean  ± SD (years)	55 ± 10	55 ± 10	38 ± 7	
Sex(F/M)	68/16	6/3	12/4	
DAS or SLEDAI T0 mean ± SD	2.33 ± 0.8	2.47 ± 0.2	5.26 ± 0.3	
DAS  or SLEDAI T1 mean± SD	2.28 ± 0.8	2.52 ± 0.2	5.41 ± 0.4	NS
DAS or SLEDAI  T2 mean ± SD	2.24 ± 0.9	2.3 ± 0.2	5.18 ± 0.3	NS




Tab 5. Systemic and local side effects in RA, SLE patients and HC
	RA BIO	RA DMARDs	SLE	HC	P
Redness/swelling injection site	5	0	1	2	NS
Fever (>37.5°C)	4	0	2	1	NS
Headache	6	1	1	3	NS
Asthenia/malaise	7	2	2	5	NS
Arthralgia/myalgia	12	2	2	4	NS
Chills	3	0	0	1	NS
Total Events/N patients	37/85 (44%)	5/9 (55%)	8/16 (50%)	16/42 (38%)	NS
N patients with events/N patients	29/85 (34%)	2/9 (22,2)	4/16 (25%)	10/42 (23%)	NS




5.2 Immunogenicity

Anti-influenza antibodies

Data on immunogenity observed in RA patients under biological agents during the three seasons are shown in tables 6-8 while those observed in RA and SLE patients on DMARDs, enrolled only in the last season, are shown in table 9.
2008/2009: RA patients did not fulfill any immunogenity criteria for A/Brisbane/59/07 (H1), 1 for B/Florida/4/06, and 3 for A/Brisbane/10/07 (H3). HC, instead,  met all the 3 criteria for A/Brisbane/59/07 (H1)  and A/Brisbane/10/07 (H3) and only one for B/Florida/4/06. However, the GMT increase was not statistically different between RA and HC for any antigen. 
2009/2010: Both HC and RA  patients fulfilled all the 3 immunogenity criteria for  the seasonal (A/Brisbane/59/07 (H1) A/Brisbane/10/07 (H3) B/Brisbane/60/08) and the pandemic (A/California/7/2009 (H1)) antigens with no statistical difference between them. 
2010/2011: RA and SLE patients under treatment with DMARDs and HC fullfilled all the 3 immunogenity criteria, while RA under treatment with  biological agents only 1 for A/Perth/16/09 (H3) and 2 for  A/California/7/2009 (H1) and B/Brisbane/60/08. 
In subjects immunized with only influenza increase in GMT versus H1(p = 0.008) and H3 (p = 0.046) was statistically different between RA under biological therapy and HC and versus H1 (p = 0.034) and B (p = 0.003) between RA under biological therapy and RA under DMARDs. 
Among HC and RA patients under treatment with DMARDs immunized also with pneumococcal vaccine no response was observed vs H3 compared to the complete response in subjects immunized with only influenza (for HC p = 0.034). Subgroups analysis is shown in figure 1-2.

Tab 6. Immunogenity in season 2008-2009 for A/Brisbane/59/07 (H1), A/Brisbane/10/07 (H3), B/Florida/4/06 in RA patients under treatment with biologicals and HC

RA/HC	H3	H1	B
SP (%)	70/100	67/100	60/55
SC (%)	56/78	33/78	33/22
SCF	3/9	2,1/6,4	2,6/3

Tab 7. Immunogenity in season 2009-2010 for A/Brisbane/59/07 (H1), A/Brisbane/10/07 (H3), B/Brisbane/60/08 and A/California/7/2009 (H1 pnd) in RA patients under treatment with biologicals and HC


RA/HC	H3	H1	B	H1 pnd
SP (%)	88/83	80/100	100/91	84/83
SC (%)	72/81	68/45	68/54	81/54
SCF	4,6/6,9	5,6/3,5	5,8/4,4	12/7,3



Tab 8. Immunogenity in season 2010-2011 for A/California/7/2009  (H1), A/Perth/16/09 (H3), B/Brisbane/60/08 in RA patients under treatment with biologicals and HC


RA/HC	H3	H1	B
SP (%)	58/89	64/94	72/94
SC (%)	35/65	50/82	39/47
SCF	3/6	4/23	2,6/5,4
RA:  rheumatoid arthritis; HC: healty controls; SP: seroprotection; SC: seroconversion; SCF: seroconversion factor



Tab 9. Immunogenity in season 2010-2011 for A/California/7/2009  (H1), A/Perth/16/09 (H3), B/Brisbane/60/08 n  SLE and RA patients under treatment with DMARDs and HC


SLE	H3	H1	B
SP	73	87	87
SC	46	86	46
SCF	5,8	31,5	6,3
RA DMARDs			
SP	78	89	78
SC	45	89	78
SCF	7,2	26,6	20,6
HC			
SP	89	94	94
SC	65	82	47
SCF	6	23	5,4
RA:  rheumatoid arthritis; DMARDs: disease modifying anti-rheumatic drugs; HC: healty controls; SLE: systemic lupus erithematosus; SP: seroprotection; SC: seroconversion; SCF: seroconversion factor



Fig 1. GMT at T0 and T1 in subgroups immunized with influenza and pneumococcal vaccines (P + I) or only influenza (I)




Fig 2. Seroconversion factor (GMT T1/GMT T0) in subgroups immunized with influenza and pneumococcal vaccines (P + I) or only influenza (I)


No significant difference in vaccine response has been observed among the different groups of biological agents (figure 3).

Fig 3. GMT at T0 and T1 in subgroups of RA patients under different biologicals



The cohort follow-up for repeated antigens revealed increase in GMT and seroprotection rate for A but not for B antigens (Figure 4). In particular, in the 6 RA patients vaccinated in the first and second seasons an increase in GMT at T0 and T1 has been observed for the reapeted antigens A/Brisbane/59/07 (H1), A/Brisbane/10/07 (H3) (figure 4A) while in the 14 RA patients vaccinated in the second and third seasons, only a slight increase at T0 and T1 has been observed for A/California/7/2009 (H1 pnd) but a strong decrease in GMT for B/Brisbane/60/08 (figure 4b). When all the RA vaccinated population is taken in consideration the seroprotection rate at T1 for the reapeted antigens reflects the above results (figure 4c).



Fig 4. A:  GMT at T0-T1-T2 in the cohort vaccinated in the first and second seasons (no 6). B: GMT at T0-T1-T2 in the cohort vaccinated in the second and third seasons (no 14). C: Seroprotection rate in all the  vaccinated RA patients for the reapeted antigens.





Anti-Pneumococcal Antibodies

Immunological response to pneumococcal vaccine (at least 2-fold or higher increase compared with the prevaccination antibody concentration) has been observed in 7/19 patirnts (37 %) for antigen 4 and in 4/19 patients (21%) for antigen 14. In HC immunological response has been observed in 4/9 (44%) for antigen 4 and in 2/9 (22%) for antigen 14.
 

5.3 Lymphocyte subpopulations

T-regulatory cells

In RA patients, Tregs were 2.7% of CD4+ lymphocytes (T0), 4% (T1) and 3.1 % (T2). The increase from T0 to T1 was statistically significant (p=0.04), as well as the decrease between T1 and T2 (p=0.04). In healthy controls, Tregs were 4.7% of CD4+ lymphocytes (T0), 5.2% (T1) and 4.9% (T2). Differences among T0, T1 and T2 were not statistically significant (Table 10). The same kinetics was observed for the absolute values. The difference between RA patients and healthy controls in Tregs (percent and absolute count) at T0 and T1 was statistically significant (p=0.02; Table 10). In RA patients, the percent and absolute count of Tregs were indirectly correlated with age (T0, r = 0.59; p=0.01) and directly with specific antibody titer to influenza vaccine H1 (at T1, r = 0.6; p=0.004 and at T2, r = 0.6; p=0.001) and H3 (at T1, r = 0.6; p=0.01 and at T2, r = 0.6; p=0.008). No significant correlations have been observed between Tregs and DAS or ANA. A decrease in the percent of CD19+, accompanied by a parallel increase of CD3+ and CD4+ lymphocytes, has also been found between T0 and T2 in both RA patients and healthy controls 



Tab 10. Vaccinated RA patients and healthy controls before (T0), 30 (T1) and 180 (T2) days after flu and pneumococcal vaccination in season 2008-2009

Lymphocite subpopulations          Vaccinated RA %                                             Healty controls %                                                                                                               T0               T1                 T2                        T0           T1              T2
  CD3+                                            69               69                  68                         69           69              72  CD4+                                            41               43                  44                         46           45              48  CD8+                                            28               26                  24                         23           24              24  CD19+                                          11                 9                  12                          8            11              10  CD4+/CD27 high/CD127low       2.7 b              4 a                 3.1                        4.7           5.2             4.9                                                                        
Data expressed as mean
a     T1vs T0,  T1vsT2 p=0.04
b        T0 healthy controls vs T0 vaccinated RA patients, P=0.02


 PMA-iono stimulated PBMC

A slight increase in activated cytokine-producing T cells at T1 compared to T0 followed by a reduction at T2 both in patients and controls have been found. Mean values were higher in patients compared to controls at every time point (n.s.). In particular, the dynamics of  CD69+IFNgamma+ cell percentages was significant for both patients and controls, whereas that of CD69+TNFalfa+ was significant only in controls (Figure 5).






Fig 5. Percentages of  activated cytokine secreting cells at T0-T1-T2 in RA patients and HC  







6. Discussion

In this study, no significant differences in SLEDAI and DAS at 30 and 180 days after flu non-adjuvanted seasonal vaccine, even administered simultaneously with an adjuvanted pandemic or polysaccharidic pneumococcal vaccines, in the second and third season respectively, have been observed. Such a relative safety of influenza vaccine administration in patients with SLE and RA appears to be present even at the immunological level, as inferred by the results of auto-antibodies measurement and lymphocyte subpopulation analysis [188–189].
No severe side effects have been observed and the mild local and systemic adverse events were not statistically different from HC, thus confirming the vaccine safety in these patients [188–193].
The outstanding immune response observed in the second season also against the non adjuvanted seasonal viral strains  is brand new compared  with our previous experience on similar patient (20% identical) and control populations, in whom the response resulted protective, but only partially meeting the CHMP criteria. 
Probably the use of an innovative and effective adjuvant such as MF59, included in the formulation of the flu pandemic vaccine, is the element able to make the difference also towards the simultaneously, but not co-locally, administered non adjuvanted flu seasonal vaccine, possibly for the innate immunity hyper-stimulation, which helps the recruitment of T helper cells, broadly reacting with shared epitopes among different viral haemagglutinins. MF59, on the other hand, may also be responsible for the slight increase of local and systemic adverse events, mainly among patients, probably because adverse events may mimic symptoms already present in RA patients. 
Adjuvanted vaccines, even though useful in immunosuppressed subjects, have seldom been used in patients with autoimmune diseases (no more than 20%, [9]), fearing  disease reactivation. 
Regarding specific immune response to pandemic influenza antigen, the current  study demonstrates that, despite patients and controls had no detectable antibody levels before vaccination, thus confirming the low percentage of cross reaction between pandemic and seasonal viral strains [189], specific post-vaccine antibody values were achieved in far higher levels and patient percentage than previously observed [138]. 
In other studies involving patients with rheumatic diseases only treated with pandemic and not seasonal vaccine, antibody levels comparable to those obtained in healthy controls have never been achieved after a single vaccine dose [190, 191, 194]. The observation of a specific antibody response to the pandemic one-dose vaccine, which is higher than that observed in healthy controls for all the three CHMP parameters, and the excellent response obtained towards the seasonal vaccine strains too, suggest that these results are a consequence of a series of factors including the MF59 adjuvant activity, the simultaneous pandemic and seasonal vaccine administration, which may take advantage of the MF59-stimulated cross reaction of  apparently antigenically divergent haemagglutinins as well as of previous natural and/or vaccine immunizations. 
The reciprocal seasonal and pandemic cross reaction is also supported by data obtained in normal adult and elderly subjects. Gasparini et al. [195], in fact, observed a doubled antibody response to the seasonal H1N1 strain when pandemic and seasonal vaccines were co-administered compared with the response obtained with the seasonal vaccine alone. In this regard Tsai [196] reported that the MF59 adjuvant stimulates production of more broadly reactive antibodies against viral strains that are mismatched to those in the vaccine. 
Thus a cross reaction and protection even in high percentage of subjects is present among apparently highly divergent viral strains, such as A[H1N1]pdm09 and seasonal strains [194,197, 198], and these shared epitopes may be recruited and stimulated with high efficiency by MF59. 
To the best of our knowledge, studies analyzing  the specific immune response to the two simultaneously administered pandemic and seasonal vaccines  in inflammatory rheumatic diseases are still not present in the literature, whereas such studies have been performed in type 1 diabetes and in healthy, including elderly, subjects [195, 199-200].  Zuccotti et al, in fact,  in eighty  type-1 diabetes young patients found an overall 100% proportion of vaccinees with protective antibody titres one month after vaccination, without significant difference between those who received either the one- or the two-dose schedule. 
The role of the adjuvant in stimulating specific immune response is also witnessed by  three studies  reporting a statistically significant reduced  GMT, seroconversion and seroprotection  rate in  RA patients (partially anti-TNF treated) compared to healthy subjects after non adjuvanted pandemic influenza vaccine administration [146, 201, 202]. 
The aim of the adjuvant is  to enhance the immune response in a population expected to be mostly naïf to the antigens and to increase the amount of vaccine produced by sparing antigens. Other potential benefits include better cross-protection against drifted influenza strains. MF-59 directly enhances antigen uptake  by activated dendritic cells, induces chemokine production and is involved in the recruitment of cells to the tissues. In humans, the adjuvant-induced immune response results in quantitatively higher antibody titres and high quality long-term persisting antibodies. These results are probably related to the induction by MF-59 of strong CD4+ T-cell help and more germinal centre reactions [203]. 
Recently Khurana et al. demonstrated that MF-59 induces the epitope spreading from HA2 to HA1, by which a much larger antigen number participates in the immune response in contrast with  the narrower recognition of the fragments of the HA2 stem region by subjects vaccinated with the non-adjuvanted or with the alum-adjuvanted vaccines, and increases the maturation of antibody affinity [204].
Seasonal and pandemic vaccines should be administered together or in close proximity to obtain better response [205], whereas the seasonal vaccine administration 3 weeks before the pandemic has been observed to be associated with a lower response to the pandemic [206,207], data observed also by Gabay et al. [194], independently of the time interval between seasonal and pandemic vaccine administrations. 
Response to seasonal influenza vaccination in RA and SLE patients under treatment with DMARDs, vaccinated in the last season,  is comparable to HC, according to the literature.
The suboptimal response observed both in RA patients under treatment with biological agents and HC in the first and third seasons could be partially due to the interference of simultaneous pneumococcal vaccination. 
Our preliminary in vitro studies, in fact, showed that the presence of the polysaccharide vaccine inhibits specific and aspecific cellular immune response towards proteic antigens in a dose-dependent manner. Larger studies to further establish these findings are warranted.
The kinetics of a specific antibody response may probably be related to the Treg dynamics after vaccination; a significant Treg increase has, in fact, been observed 30 days after vaccination compared to the baseline values, in direct significant correlation with the specific anti-H1 and H3 antibodies, thus suggesting a fine regulatory activity on the antibody response, probably consequent to the re-equilibrium induced by TNFα blockers [208–208]. TNFα is able, in fact, to interact with Tregs via some receptors expressed on their surface, improving their function [209–211]. 
No studies have been published on Treg kinetics in immunized people to our knowledge, except two papers on Bacillus Calmette-Guérin (BCG) [212] and hepatitis B [213] vaccines, which report Treg increase. Data presented here seem thus original and in line with the cited reports. The observed inverse correlation of Tregs with age is in agreement with the literature [214] and confirms that the regulatory lymphocyte subpopulation is an expression of such a delicate activity that tends to progressively decrease with the growing age.
Cellular immune response plays a crucial role in clearing influenza infection, furthermore in elderly people it correlates with protection more than serum antibody response [215]. Recent studies reported normal cellular immune response in RA patients treated with Rituximab [144] and in Wegener and scleroderma patients [216, 217], while it is diminished in SLE patients [182]. Cellular immune response to influenza vaccine has never been investigated in RA patients treated with anti-TNF or Abatacept. In the current study stimulated CD69 positive T cells presented a similar profile between patients and healthy controls,  with a cytokine pattern of T1 (IFN/TNF secreting cells) and T17 (IL17 secreting cells), and with a dynamics showing an increase a month after vaccine stimulation and a decrease at lower than baseline values at six months, which is coherent of what has been  observed with T regulatory cells
The increase in activated T cells producing IFNγ at T1 time point reflects the major implication of TH1 response to vaccination. The non significant increase in T activated TNF+ in patients is likely due to their theraphy. Il 17 does not seem particularly involved in influenza response even though further studies are needed to provide a definitive answer to this question.
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